- Home
- FEDU vs EVAX Comparison
FEDU vs EVAX Comparison
Compare FEDU & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEDU
- EVAX
- Stock Information
- Founded
- FEDU 2007
- EVAX 2008
- Country
- FEDU China
- EVAX Denmark
- Employees
- FEDU N/A
- EVAX N/A
- Industry
- FEDU
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FEDU
- EVAX Health Care
- Exchange
- FEDU NYSE
- EVAX Nasdaq
- Market Cap
- FEDU 20.0M
- EVAX 16.3M
- IPO Year
- FEDU 2017
- EVAX 2021
- Fundamental
- Price
- FEDU $6.96
- EVAX $1.31
- Analyst Decision
- FEDU
- EVAX Strong Buy
- Analyst Count
- FEDU 0
- EVAX 2
- Target Price
- FEDU N/A
- EVAX $10.00
- AVG Volume (30 Days)
- FEDU 16.5K
- EVAX 74.6K
- Earning Date
- FEDU 12-20-2024
- EVAX 05-27-2025
- Dividend Yield
- FEDU 32.71%
- EVAX N/A
- EPS Growth
- FEDU N/A
- EVAX N/A
- EPS
- FEDU 0.12
- EVAX N/A
- Revenue
- FEDU $27,971,139.00
- EVAX $3,344,000.00
- Revenue This Year
- FEDU N/A
- EVAX $102.45
- Revenue Next Year
- FEDU N/A
- EVAX $100.30
- P/E Ratio
- FEDU $58.40
- EVAX N/A
- Revenue Growth
- FEDU 141.14
- EVAX 4480.82
- 52 Week Low
- FEDU $3.69
- EVAX $1.20
- 52 Week High
- FEDU $22.70
- EVAX $22.05
- Technical
- Relative Strength Index (RSI)
- FEDU 38.85
- EVAX 29.55
- Support Level
- FEDU $5.50
- EVAX $1.20
- Resistance Level
- FEDU $6.80
- EVAX $1.46
- Average True Range (ATR)
- FEDU 1.20
- EVAX 0.13
- MACD
- FEDU -0.13
- EVAX 0.01
- Stochastic Oscillator
- FEDU 47.13
- EVAX 16.52
About FEDU FOUR SEASONS EDUCATION (CAYMAN) INC SPON ADS EACH REP 10 ORD SHS(R/S)
Four Seasons Education (Cayman) Inc is engaged in the provision of after-school education services for kindergarten, elementary and middle school students. The Company derives its revenue from learning services, tourism services, and learning technology and content solutions. The company is a comprehensive educational enterprise that provides research practice services, educational informatization equipment, high-quality educational resources, and teacher training, as well as a digital publishing business, and continues to expand in educational research and educational informatization.
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.